The Patient-Reported Outcomes Project of HCV-TARGET
NCT02601820 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1601
Last updated 2019-09-16
Summary
The PROP UP research study is funded by The Patient Centered Outcomes Research Institute (PCORI). PROP UP is a multi-centered prospective observational study that will evaluate all-oral treatment regimens for chronic hepatitis C viral (HCV) infection regarding several patient-reported outcomes (PROs) such as HCV-associated symptoms, treatment side effects, medication adherence, out of pocket costs, comorbid conditions, and long-term benefits of cure and harms of treatment to compare PROs of different treatment regimens, treatment durations, and patient subgroups. Participants will be recruited from 9 U.S. liver centers. Approximately 1920 patients with HCV infection who are prescribed a regimen containing Sofosbuvir/Ledipasvir(SOF/LED), SOF/Velpatasvir(SOF/VEL), Grazoprevir/Elbasvir(GRZ/ELB), OBV/PTV/r + DSV (PRoD), or daclatasvir/SOF (DAC/SOF) will be recruited and approximately 1600 patients who are approved and begin HCV treatment will be enrolled in the longitudinal study. PRO surveys will be evaluated before, during and after HCV treatment.
PROP UP is a collaborative effort between behavioral and biomedical researchers, a patient engagement group and a patient advocacy organization.
Conditions
- Hepatitis C, Chronic
- Liver Diseases
Sponsors & Collaborators
-
Patient-Centered Outcomes Research Institute
collaborator OTHER -
University of North Carolina, Chapel Hill
lead OTHER
Principal Investigators
-
Donna M. Evon, PhD · University of North Carolina, Chapel Hill
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2018-07-31
- Completion
- 2018-07-31
Countries
- United States
Study Locations
More Related Trials
-
PoC-HCV Genedrive Viral Detection Assay Validation Study
NCT02992184 ·Status: COMPLETED
-
A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C
NCT01331850 ·Status: COMPLETED ·Phase: PHASE2
-
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
NCT01628094 ·Status: COMPLETED ·Phase: PHASE2
-
Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment
NCT03480269 ·Status: UNKNOWN
-
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
NCT01220947 ·Status: COMPLETED ·Phase: PHASE2
-
Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)
NCT01937728 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
NCT00255034 ·Status: TERMINATED ·Phase: PHASE4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
NCT03520660 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
NCT00308048 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1
NCT01185860 ·Status: COMPLETED ·Phase: PHASE1
-
HCV Test and Treat Utilizing Simplified HCV Patient Education
NCT05582681 ·Status: TERMINATED ·Phase: PHASE4
-
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
NCT02065999 ·Status: COMPLETED
-
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
NCT00801255 ·Status: COMPLETED ·Phase: PHASE1
-
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
NCT00543244 ·Status: UNKNOWN
-
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
NCT01749150 ·Status: COMPLETED ·Phase: PHASE2
-
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
NCT02455167 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
NCT00790673 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens
NCT03366610 ·Status: COMPLETED
-
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
NCT03603327 ·Status: COMPLETED ·Phase: NA
-
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C
NCT02526641 ·Status: COMPLETED
-
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
NCT00709228 ·Status: COMPLETED
-
Long Term Follow-up of Hepatitis C Cured Patients
NCT03246048 ·Status: COMPLETED
-
Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1
NCT01226771 ·Status: COMPLETED ·Phase: PHASE3
-
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile
NCT00272389 ·Status: UNKNOWN
-
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907 ·Status: COMPLETED